Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 follow-up study of bilateral AAV5-hRKp.RPGR gene therapy in RPGR-associated X-linked retinitis pigmentosa
NL-OMON51971Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botaretigene sparoparvovec in retinitis pigmentosa (RP) and Genetic Eye Disease, sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in binocular vision-guided mobility assessment, Adverse events and 1 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
retinitis pigmentosa (RP)Genetic Eye Disease
Beyond the preview
Go deeper on NL-OMON51971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51971.